Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Rare Diseases
Rare Diseases · The big question

A $270M Bet on a Rare Disease Drug Hits a Major Snag

BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal

Fierce Biotech1 min readAI-assisted summary
Editorial illustration for BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
Editorial illustration

Summary

Pharmaceutical company BioMarin placed a massive $270 million bet on a new treatment developed by Inozyme. The experimental treatment is an enzyme replacement therapy, which is a medical approach designed to supply the body with a crucial protein that it cannot produce on its own. Researchers have been rigorously testing this therapy in a clinical trial for children who suffer from a rare genetic disorder.

To prove the drug works, the late-stage study, known as a Phase 3 trial, was designed with two main markers for success. In clinical research, these main goals are called primary endpoints. Unfortunately, the therapy only managed to achieve one of these two targets. By missing a key goal and delivering mixed results, the drug candidate failed to fully demonstrate its effectiveness.

Why it matters.

The failure to meet all study goals casts a heavy shadow over the future of this treatment. Because the therapy only showed partial success in its Phase 3 trial, it faces serious doubts regarding its regulatory approval and commercial viability. If the drug cannot pass regulatory scrutiny, BioMarin's $270 million financial investment could be lost.

Beyond the financial blow to the industry, these mixed results represent a frustrating setback for families seeking help. Developing drugs for rare diseases is incredibly challenging. When a therapy reaches the final stages of testing and falls short, it means children with this rare genetic disorder are left waiting even longer for a reliable and fully proven medical solution.

From the source

The story in numbers.

Investment value
$270 million
Primary endpoints met (out of dual endpoints)
1
Clinical trial stage
Phase 3
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Rare Diseases

A Potential First Treatment for Stiff Person Syndrome

People living with stiff person syndrome currently have zero approved medicines designed specifically to treat their condition. However, a glimmer of hope is on the horizon. A biotechnology company named Kyverna Therapeutics is actively nearing regulatory approval for a new approach to managing the disease. This proposed treatment relies on CAR-T cell therapy. In this type of medicine, scientists take a patient's own immune cells and genetically modify them in a laboratory so they can track down and eliminate specific disease-causing cells in the body. While traditionally known as a powerful tool against certain blood cancers, researchers are now applying this advanced technology to complex neurological and autoimmune disorders. Although the prospect of a first-ever approved treatment is exciting, the medical community is still waiting on the fine print. Current reports are brief and lack the detailed clinical data needed to fully evaluate the medicine. Crucial details regarding how many patients were tested, the potential side effects, and exact measurements of how well the therapy works have not yet been fully disclosed to substantiate the impending approval.

Labiotech.eu1 min read
Rare Diseases

How a tiny worm solved a genetic mystery in a rare brain disorder

Our brain cells communicate by passing chemical signals, a process controlled by tiny gates called ion channels. When the genes instructing these gates carry a mutation, it can cause severe neurological disorders. Generally, doctors classify these mutations into two straightforward categories. A loss-of-function mutation means the gates are closed or broken, while a gain-of-function mutation means the gates are stuck open. However, researchers recently encountered a patient with a mutation in a calcium channel gene called CACNA1A whose symptoms bafflingly fit into both categories at once. To solve this clinical mystery, scientists first tested the mutation in standard lab dishes using isolated cells. This traditional method completely missed the dual nature of the disease, falsely indicating that the mutation only caused a severe loss of channel function. Realizing they needed a more complete picture, the team engineered the exact genetic variant into a microscopic worm called C. elegans to observe the mutation in a living nervous system. The worms revealed a fascinating paradox. Even though the mutation resulted in fewer calcium channels overall, the channels that did exist misbehaved. Computer simulations and electrical recordings showed that the faulty gates lingered in a partially open state, allowing calcium to leak into the cells while they were supposed to be resting. This constant leak triggered an unwanted release of chemical signals, perfectly explaining how a single mutation could cause such a confusing mix of clinical symptoms.

bioRxiv2 min read
Rare Diseases

New Drug Shows Early Promise for Rare Vascular Diseases

A new experimental drug called zovegalisib is showing early promise for patients with rare blood vessel conditions known as vascular anomalies and PROS. Developed by Relay Therapeutics, the medication works by blocking a specific genetic target called PIK3CA, an enzyme that is often involved in abnormal tissue growth. In early testing, zovegalisib has demonstrated striking results compared to the current standard treatment, Novartis' drug Vijoice. While the older medication historically shrinks tissue overgrowths in 11 to 27 percent of patients, Relay's new drug achieved response rates of 43 percent at lower doses and a remarkable 100 percent at higher doses. Beyond working more effectively, it also appears to be much gentler on patients. Severe side effects occurred in just 9 percent of those taking zovegalisib, a sharp drop from the 30 to 71 percent severe side effect rate seen in previous studies of Vijoice. However, researchers caution that these findings come from an early-stage clinical trial. Scientists still need to conduct additional testing using different dosing schedules to find the perfect balance between keeping the drug highly effective and maintaining its strong safety profile.

BioPharma Dive1 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
A $270M Bet on a Rare Disease Drug Hits a Major Snag — Daily Strand